Side Effects of hCG
Human chorionic gonadotropin (hCG) carries serious risks including ovarian hyperstimulation syndrome, arterial thromboembolism, fluid retention, and anaphylaxis, with the FDA specifically warning about these complications particularly when used with fertility treatments. 1
Serious/Life-Threatening Side Effects
The FDA drug label identifies the following principal serious adverse reactions 1:
- Ovarian hyperstimulation syndrome: Sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion (in women receiving fertility treatment)
- Arterial thromboembolism: Multiple case reports document deep vein thrombosis and pulmonary embolism, including a 64-year-old woman who developed bilateral pulmonary emboli just 2 weeks after starting hCG diet 2, and a 28-year-old with superior mesenteric vein thrombosis 3
- Rupture of ovarian cysts with resultant hemoperitoneum
- Anaphylaxis with urinary-derived hCG products 1
- Multiple births (when used for fertility treatment)
Common/Moderate Side Effects
Fluid Retention and Related Complications
hCG induces androgen secretion which may cause fluid retention, requiring caution in patients with 1:
- Cardiac disease
- Renal disease
- Epilepsy
- Migraine
- Asthma
Endocrine Effects
- Precocious puberty in pediatric patients treated for cryptorchidism—therapy must be discontinued if signs develop 1
- Cross-reactivity in radioimmunoassays for gonadotropins, especially luteinizing hormone, potentially causing false laboratory results 1
Reproductive/Oncologic Concerns
- Sporadic testicular tumors reported in otherwise healthy young men receiving hCG for secondary infertility, though causative relationship not definitively established 1
- Congenital anomalies: Combined hCG/gonadotropin therapy induced high incidences of external congenital anomalies in animal studies (dose-dependent in mice) 1
Rare/Unusual Side Effects
- Visual disturbances: Blurred vision and scotomas reported, similar to clomiphene-induced visual effects 4
- Exacerbation of acute intermittent porphyria: A 34-year-old woman developed severe symptoms including abdominal pain, neuropathy, and electrolyte abnormalities after hCG injections for weight loss 5
Context-Specific Risks
When Used for Male Hypogonadism
The most recent evidence from 2022 showed hCG monotherapy in men with hypogonadal symptoms was well-tolerated with no thromboembolic events and no changes in hematocrit, PSA, or hemoglobin A1c 6. This contrasts sharply with the weight-loss diet context.
When Used for Weight Loss (Off-Label)
This use is particularly dangerous and not evidence-based 7. The hCG diet has no proven efficacy and carries disproportionate risks, with multiple documented cases of thromboembolism 2, 3.
Critical Caveats
- Benzyl alcohol in diluent: The recommended diluent contains benzyl alcohol 0.9%, which has been associated with fatal "Gasping Syndrome" in premature infants 1
- Pregnancy contraindication: hCG is absolutely contraindicated in pregnancy 1
- Not FDA-approved for weight loss: All weight-loss uses are off-label and potentially dangerous 7
- Laboratory interference: Physicians must inform laboratories when patients are on hCG if gonadotropin levels are requested 1
Safety Profile by Indication
For hypogonadotropic hypogonadism (FDA-approved use): When properly dosed (500-2500 IU, 2-3 times weekly) and monitored, hCG appears relatively safe with the main concerns being fluid retention and need for testosterone monitoring 8, 9.
For weight loss (not FDA-approved): Unacceptable risk-benefit ratio with documented serious thromboembolic complications and no proven efficacy 2, 3, 7.